

**Draft agenda**  
**25<sup>th</sup> meeting of the Biocidal Products Committee (BPC)**  
**25-26 April 2018**  
**ECHA Conference Centre, Annankatu 18, Helsinki**  
**Starts on 25 April at 09:30,**  
**ends on 26 April at 16:00**

1. – Welcome and apologies

2. – Agreement of the agenda

BPC-A-25-2018  
*For agreement*

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-24

BPC-M-24-2017  
*For agreement*

5. – Administrative issues

5.1. Housekeeping issues

*For information*

5.2. Other administrative issues and report from other Committees

BPC-25-2018-01  
*For information*

## 6. – Work programme for BPC

### 6.1. Revised BPC Work Programme 2018-2019

BPC-25-2018-02  
**For information**

### 6.2. Outlook for BPC

BPC-25-2018-03  
**For information**

## 7. – Applications for approval of active substances\*

### 7.1. Draft BPC opinion on active chlorine generated from sodium chloride by electrolysis for PT 1, 2, 3, 4 and 5 and for active chlorine released from hypochlorous acid for PT 1, 2, 3, 4 and 5

*Previous discussion(s): WG-IV-2017, WG-I-2018 (APCP only)*

#### **Active chlorine generated from sodium chloride by electrolysis:**

**PT1:** BPC-25-2018-04A, B, C

**PT2:** BPC-25-2018-05A, B, C

**PT3:** BPC-25-2018-06A, B, C

**PT4:** BPC-25-2018-07A, B, C

**PT5:** BPC-25-2018-08A, B, C

#### **Active chlorine released from hypochlorous acid:**

**PT1:** BPC-25-2018-09A, B, C

**PT2:** BPC-25-2018-10A, B, C

**PT3:** BPC-25-2018-11A, B, C

**PT4:** BPC-25-2018-12A, B, C

**PT5:** BPC-25-2018-13A, B, C

**For adoption**

### 7.2. Draft BPC opinion on carbendazim for PT 7 and 10

*Previous discussion(s): WG-II-2015*

**PT7:** BPC-25-2018-14A, B, C

**PT10:** BPC-25-2018-15A, B, C

**For adoption**

### 7.3. Draft BPC opinion on *Willaertia Magna C2c Maky* for PT 11

*Previous discussion(s): WGMO-2, WGMO-3*

BPC-25-2018-16A, B, C

**For adoption**

---

\* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

**7.4. Assessment of endocrine disrupting properties in active substance approval**

*Previous discussion(s): BPC-24*

BPC-25-2018-17

***For agreement***

**Item 8 – Union authorisation**

**8.1 Update on Union authorisation**

**8.2 Proposal on the “fast-track procedure” on Union authorisation**

BPC-25-2018-18

***For agreement***

**Item 9 – Any other business**

**Item 10 – Action points and conclusions**

***For agreement***

**Provisional time schedule for the  
25<sup>th</sup> meeting of the Biocidal Products Committee (BPC)  
ECHA Conference Centre, Annankatu 18, Helsinki  
25 April 2018: starts at 09:30; 26 April ends at 16:00**

Please note that the time schedule indicated below are provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following day for BPC opinions.

**Wednesday 25 April: morning session**

- |           |   |
|-----------|---|
| Items 1-5 | Opening items and administrative issues   |
| Item 6    | Work programme of the BPC 2018-19   |
| Item 7.1  | Draft BPC opinion on active chlorine generated from sodium chlorite by electrolysis for PT 1, 2, 3, 4 and 5 and for active chlorine released from hypochlorous acid for PT 1, 2, 3, 4 and 5 |

**Wednesday 25 April: afternoon session**

- |          |  |
|----------|--|
| Item 7.1 | (cont'd)   |
| Item 7.2 | Draft BPC opinion on carbendazim for PT 7 and 10 |

**Thursday 26 April: morning session**

- |          |  |
|----------|--|
| Item 7.3 | Draft BPC opinion on Willaertia Magna C2c Maky for PT 11 |
|----------|--|

**Thursday 26 April: afternoon session**

- |          |  |
|----------|--|
| Item 8.1 | Update on Union authorisation  |
| Item 8.2 | Proposal on the "fast-track procedure" on Union authorisation              |
| Item 7.4 | Assessment of endocrine disrupting properties in active substance approval |
| Item 9   | AOB  |
| Item 10  | Action points and conclusions  |

End of meeting

oOo